Clinical efficacy of gamma-hydroxybutyric acid in treatment of opiate withdrawal
- 1 September 1994
- journal article
- case report
- Published by Springer Nature in Archiv Fur Psychiatrie Und Nervenkrankheiten
- Vol. 244 (3) , 113-114
- https://doi.org/10.1007/bf02191883
Abstract
This paper describes the role of gamma-hydroxybutyric acid (GHB) in the treatment of opiate withdrawal syndrome. In the two patients described, after having abruptly withdrawn from long-term methadone treatment, GHB was orally administered (each dose given every 4–6 h) for 8–9 days. The GHB showed both a high efficacy (some mild and transient symptoms attributable to opiate withdrawal were observed, but only in the first days of therapy) and a good tolerability (no clinical phenomena interpreted as GHB side effects were found). These results could be of interest in improving the pharmacological treatment of drug addiction.Keywords
This publication has 6 references indexed in Scilit:
- Gamma‐Hydroxybutyric Acid in the Treatment of Alcohol Dependence: A Double‐Blind StudyAlcohol, Clinical and Experimental Research, 1992
- SUPPRESSION BY GAMMA-HYDROXYBUTYRIC ACID OF ETHANOL WITHDRAWAL SYNDROME IN RATSAlcohol and Alcoholism, 1989
- GAMMA-HYDROXYBUTYRIC ACID FOR TREATMENT OF ALCOHOL WITHDRAWAL SYNDROMEThe Lancet, 1989
- Function of γ-hydroxybutyrate: a putative neurotransmitterBiochemical Society Transactions, 1987
- Suppression of voluntary ethanol consumption in rats by gamma-butyrolactoneLife Sciences, 1983
- Rating the presence and severity of opiate dependenceClinical Pharmacology & Therapeutics, 1974